Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ConMed Corp.

Division of Conmed Corp.
www.conmed.com

Latest From ConMed Corp.

Orthobiologics Market Well-Positioned For Innovative Reconstruction

Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.

Orthopedics Cellular & Genetic

Market Dynamics Switchover To Come In Fast-Growing Soft Tissue Fixation Segment

Global sales for arthroscopy and sports medicine devices are predicted to hit $6.5bn by 2021. This will be driven by the fast-growing soft tissue fixation products segment: significant changes in market dynamics are expected over the next few years, as hip fixation procedures pick up pace. This article delves into the landscape of the soft tissue fixation device market, as well as the four key segments in the arthroscopy devices space. It will also analyze the key players in these markets, highlight trends and discuss the biggest challenges.

Orthopedics Surgical Procedures

Teleflex Bets Percutaneous Laparoscopy Will Be MIS Game Changer

Story and Podcast: Teleflex Medical launched in March a novel portfolio of miniaturized percutaneous surgical instruments that have the same functionality as full-sized laparoscopic instruments, but allow surgeons to access the abdominal cavity using trocar-less entry and much smaller incisions than those required in traditional laparoscopy. Teleflex execs say the technology is a game changer, and the company hopes percutaneous laparoscopy will become the standard of care for the 4 million laparoscopic procedures performed annually in the US.

Medical Device Innovation

Device/Diagnostics Quarterly Deal Statistics, Q4 2015

At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.

Medical Device Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register